Alterations in the disposition of differently cleared drugs in patients with cirrhosis
- 1 August 1979
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 26 (2) , 221-227
- https://doi.org/10.1002/cpt1979262221
Abstract
We have compared the disposition of antipyrine orally (15 mg/kg) and the new antiarrhythmic drug lorcainide intravenously (1.5 mg/kg) in 8 patients with alcoholic cirrhosis. Antipyrine (AP) serves as a model drug for drugs which are eliminated independently of liver blood flow and lorcainide (L) elimination as a model for drugs which depend on liver blood flow. Since in healthy subjects elimination half‐life (t½) of L increased with age (r = 0.68, p < 0.01) due to parallel change in the volume of distribution (r = 0.52, p < 0.05), its disposition had to be compared to age‐matched controls. Elimination of both AP and L was impaired in cirrhotic patients, expressed either in terms (mean ± SD) of t½ (AP = 26.8 ± 15.0 hr and 12.3 ± 1.8; L = 12.5 ± 4.5 hr and 7.7 ± 2.2 hr, p = 0.002) or of clearance (Cl) (AP = 21.9 ± 7.9 ml/min and 41.7 ± 5.5 ml/min; L = 814 ± 144 and 1002 ± 304 ml/min, p = 0.06). While the alterations in plasma Cl were great for AP, they were smaller for L. This suggests that elimination of drugs in cirrhotic patients is associated with relatively more impairment of enzyme activity than of hepatic blood flow. The slightly decreased Cl of L in patients with alcoholic cirrhosis would suggest that L should be carefully handled in patients with dysfunction of the liver.This publication has 7 references indexed in Scilit:
- Mechanism for reduced drug clearance in patients with cirrhosisGastroenterology, 1978
- CLINICAL EXPERIENCE WITH LORCAINIDE (R 15 889), A NEW ANTI-ARRHYTHMIC DRUG1977
- Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: Lidocaine and indocyanine greenClinical Pharmacology & Therapeutics, 1976
- The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver diseaseClinical Pharmacology & Therapeutics, 1976
- Lidocaine Pharmacokinetics in Advanced Heart Failure, Liver Disease, and Renal Failure in HumansAnnals of Internal Medicine, 1973
- Shortcomings in Pharmacokinetic Analysis by Conceiving the Body to Exhibit Properties of a Single CompartmentJournal of Pharmaceutical Sciences, 1968
- USE OF INDOCYANINE GREEN IN MEASUREMENT OF HEPATIC BLOOD FLOW AND AS A TEST OF HEPATIC FUNCTION1961